Trialbee Announces the Release of HIVE, the Smartest Way to Leverage Real-World Data in Patient Recruitment
Trialbee, a leading global technology provider for patient matching and engagement in clinical trials, today announced the release of HIVE™, a smart data science application applied on Real World Data (RWD) to enhance targeting and precision in performance-driven patient recruitment for global clinical trials.
“Traditional patient recruitment has limited access to patients and takes a long time to accomplish. Digital advertising for clinical trials, to supplement the pool of patients available to investigators, often results in large burdensome screening activities for the sites only to result in a few additional patients to enroll. Trialbee HIVE uses a smart modeling technique and expands the pool of potential clinical trial participants and then narrows down the pool to only the most relevant candidates matching the study criteria. The multi-sourcing of patients from large RWD repositories provides sites with a steady flow of motivated and study-ready patients allowing sites to focus on the final clinical evaluation prior to enrollment,” said Lollo Eriksson, Chief Strategy Officer at Trialbee.
Trialbee HIVE is a result of combined expertise and close collaboration with Trialbee partner organizations specializing in global health research networks, RWD management, advanced data science techniques, consumer data connectivity platforms and eClinical technologies. “We are proud of the integration work between these innovative institutions and organizations, and to be able to offer Trialbee HIVE to sponsors, clinical research organizations and investigators engaged in clinical research,” said Matt Walz, CEO of Trialbee.
“The ability to simulate an eligible cohort with RWD and safely connect, qualify and scale with measurable outcomes is a critical step to achieve the precision needed to understand and target the patient population for a trial. A steppingstone capability to strategic clinical study management and improvement of the recruitment approach is to use this information to access and engage a large number of patients using smart matching techniques to ensure a diverse study population,” said Mats Sundgren, Director of Health Informatics, Astra Zeneca.
The most prescient challenges facing pharmaceutical research & development (R&D) are slow patient recruitment and large numbers of dropouts from clinical trials, causing significant delays and increasing costs for pharmaceutical products to reach the marketplace. The Trialbee solution is designed to manage and accelerate the patient recruitment process and maintain patient engagement by incorporating data-driven digital solutions in clinical trials and optimizing protocol design and site selection.
Trialbee is a world leading technology provider in patient matching and engagement, empowering patients to participate in clinical trials as a care option. Founded in 2010, Trialbee has continuously innovated patient-centric technology solutions for global clinical trials. Trialbee – Dedicated to patients; driven by science; and powered by data. For more information, visit trialbee.com and contact us at email@example.com.
Kristi Lee-John for Trialbee
Tel.: +1 919-270-8054
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa’s Mission to Digitally Enable Small Businesses Gains Momentum Across Europe1.3.2021 10:00:00 CET | Press release
Visa (NYSE: V) today announced more than 100 partners across Europe have joined the Where You Shop Matters initiative to help small business owners build digital capabilities and continue serving their communities. More than two million small firms across Europe have received support since the launch of the program in summer 2020. The announcement marks a major milestone in Visa’s commitment to help eight million small and medium sized businesses (SMBs) in Europe – and 50 million globally - to get online, adapt and future proof their business. Across Europe, Covid-19 continues to have a devastating impact on small businesses. Research conducted by Visa revealed that 65% of small businesses are concerned about the future of their business.1 With many having to operate under restrictions and lockdowns, small businesses are increasingly moving their operations online and embracing digital payments. Visa data shows that over 10 countries in Europe have seen a 20% increase in online sales a
Northern Trust Asset Management’s FlexShares ® Enters European ETF Market1.3.2021 10:00:00 CET | Press release
Northern Trust Asset Management’s FlexShares Exchange Traded Funds today announced the launch of two climate focused exchange traded funds (ETFs): the FlexShares® Developed Markets Low Volatility Climate ESG UCITS ETF (QVFD) and the FlexShares® Developed Market High Dividend Climate ESG UCITS ETF (QDFD). The Funds represent FlexShares’ first ETFs available in Europe, with additional funds planned to launch in the coming months. “We’re pleased to present the first FlexShares products in Europe, which reflect Northern Trust Asset Management’s three decades of experience in managing sustainability-focused investment strategies,” said Marie Dzanis, head of Europe, Middle East and Africa (EMEA). “Actively designed with the transparency of indexing, these two ETFs are built specifically to fit within EMEA investors’ evolving needs to help manage portfolio volatility and deliver income in a low yield environment while doing so with a focus on quality.” Both strategies will utilize Northern Tr
Effissimo Releases Presentation Explaining Proposal to Appoint Independent Investigators at Toshiba1.3.2021 08:00:00 CET | Press release
Effissimo Capital Management (“Effissimo”), the largest shareholder of Toshiba Corporation (“Toshiba”) (TYO:6502) through the funds it manages, today released a presentation explaining the reasons behind its proposal for an independent investigation into reported irregularities surrounding Toshiba’s July 2020 Annual General Meeting of Shareholders (“AGM”). Effissimo’s proposal will be voted on by Toshiba’s shareholders at an extraordinary shareholders meeting scheduled for March 18, 2021. The full proposal in English can be found here. Supplementing its letter to shareholders dated February 24, 2021, Effissimo’s presentation explains its proposal for an independent investigation into the irregular handling of shareholder voting and shareholder pressure at the closely contested AGM, which Toshiba’s conflicted Audit Committee’s self-audit fails to address. The presentation provides data showing discrepancies in the claimed delivery times of mailed ballots said by Toshiba’s vote tabulator
Mobidiag Receives CE-IVD Marking for Amplidiag ® RESP-4 for Simultaneous Detection of COVID-19, Flu A, Flu B and RSV1.3.2021 07:00:00 CET | Press release
Mobidiag Ltd. today announces that it has received CE-IVD marking for its https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmobidiag.com%2Fproducts%2Famplidiag%2F%23ad-resp-4&esheet=52387757&newsitemid=20210228005031&lan=en-US&anchor=Amplidiag%26%23174%3B+RESP-4&index=1&md5=0cd23e123f09386349b0cce93993cf54 Amplidiag® RESP-4 molecular diagnostic test for the rapid and simultaneous detection of some of the most prevalent respiratory viruses: SARS-CoV-2 (responsible for COVID-19 infection), Influenza A, Influenza B and RSV. These viruses present similar symptoms, making it difficult for physicians to determine accurately which virus a patient has. The https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmobidiag.com%2Fproducts%2Famplidiag%2F%23ad-resp-4&esheet=52387757&newsitemid=20210228005031&lan=en-US&anchor=Amplidiag%26%23174%3B+RESP-4&index=2&md5=464a0549cf8a17c939d070d2af83d1a7 Amplidiag® RESP-4 assay can rapidly and simultaneously determine an accurate
CLH Evolves to Exolum, the Company’s New Global Brand1.3.2021 06:00:00 CET | Press release
Exolum is the new brand name chosen by the CLH Group from now on to face its ambitious objectives for the future, focused on adapting its business to decarbonisation and the energytransition, the digitalisation of its activities and the fight against climatechange. This rebranding is due to the need to adapt to the new environment and to transform the company itself which, in addition to carrying out oil product storage and transport activities in Spain, has embarked on an international growth process and is now present in 7 othercountries. The group has expanded its activity to the storage, management and transportation of liquid products, especially chemical products, operating in new sectors, such as eco-fuels, the circulareconomy and the development of new energyvectors. The new name, simple but modern, shows a spirit where innovation is the key. The Exolum brand was originally devised as the CLH Group subsidiary dedicated to entrepreneurship and innovation. However, after several
CGTN: What Are Generations of Chinese Communists Striving For?27.2.2021 16:36:00 CET | Press release
The Communist Party of China (CPC), the ruling party of the world's most populous nation and the second largest economy, is turning 100 this year. What has been motivating the CPC to fight against one challenge after another over the past century? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210227005021/en/ "The original aspiration and the mission of Chinese Communists is to seek happiness for the Chinese people and rejuvenation for the Chinese nation," General Secretary Xi Jinping of the CPC Central Committee said in his report to the 19th CPC National Congress in October 2017. "This founding aspiration, this mission, is what inspires the Chinese Communists to advance," Xi said. Self-discipline, selflessness In March 2018, Xi, also the Chinese president, further explained the cause pursued by the CPC with a quote from an ancient poem: "A virtuous person is as sharp-sighted as a clear mirror hanging high, a selfless perso
Colicity Inc. Announces Closing of $345 Million Initial Public Offering26.2.2021 23:00:00 CET | Press release
Colicity Inc. (the “Company”) announced the closing today of its initial public offering of 34,500,000 units, including the underwriters’ exercise of their full over-allotment option for 4,500,000 units, at a price of $10.00 per unit. The units are listed on the NASDAQ Stock Market (NASDAQ) and began trading under the ticker symbol “COLIU” on February 24, 2021. Each unit consists of one Class A share and one-fifth of one redeemable warrant, with each whole warrant exercisable to purchase one Class A share at a price of $11.50 per share. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the Class A shares and warrants are expected to be listed on the NASDAQ under the symbols “COLI” and “COLIW,” respectively. Colicity Inc. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company int
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom